Agustsson Thorhallur, Rydén Mikael, Hoffstedt Johan, van Harmelen Vanessa, Dicker Andrea, Laurencikiene Jurga, Isaksson Bengt, Permert Johan, Arner Peter
Department of Surgery, Karolinska Institutet at Karolinska University Hospital, Stockhom, Sweden.
Cancer Res. 2007 Jun 1;67(11):5531-7. doi: 10.1158/0008-5472.CAN-06-4585.
Loss of fat mass is a key feature of cancer cachexia and has been attributed to increased adipocyte lipolysis. The mechanism behind this alteration is unknown and was presently investigated. We studied mature s.c. fat cells and differentiated preadipocytes from 26 cancer patients with and without cachexia. Hormone-induced lipolysis and expression of lipolysis-regulating genes were determined together with body composition and in vivo lipolytic activity (fasting plasma glycerol or fatty acids related to body fat). Body fat was reduced by 40% and in vivo lipolytic activity was 2-fold increased in cachexia (P = 0.001). In mature adipocytes, the lipolytic effects of catecholamines and natriuretic peptide were 2- to 3-fold increased in cachexia (P < 0.001). This was completely counteracted by inhibiting the rate-limiting lipolysis enzyme hormone-sensitive lipase (HSL). In cachexia, the expression levels of HSL mRNA and protein were increased by 50% and 100%, respectively (P = 0.005-0.03), which strongly correlated with in vitro lipolytic stimulation (r = 0.7-0.9). The antilipolytic effect of insulin in mature fat cells and the stimulated lipolytic effect in differentiated preadipocytes were unaltered in cachexia. Patients who lost weight due to other factors than cancer cachexia had no change in adipocyte lipolysis. In conclusion, adipocyte lipolysis is increased in cancer cachexia not due to nonepigenic factors or to weight loss per se, but most probably because of enhanced expression and function of adipocyte HSL. The selective inhibition of this enzyme may prevent fat loss in cancer patients.
脂肪量减少是癌症恶病质的一个关键特征,且一直被认为是脂肪细胞脂解增加所致。这种改变背后的机制尚不清楚,目前对此展开了研究。我们研究了26例有或无恶病质的癌症患者的成熟皮下脂肪细胞和分化的前脂肪细胞。测定了激素诱导的脂解作用和脂解调节基因的表达,同时还测定了身体成分和体内脂解活性(空腹血浆甘油或与体脂相关的脂肪酸)。恶病质患者的体脂减少了40%,体内脂解活性增加了2倍(P = 0.001)。在成熟脂肪细胞中,恶病质患者体内儿茶酚胺和利钠肽的脂解作用增加了2至3倍(P < 0.001)。通过抑制限速脂解酶激素敏感性脂肪酶(HSL),这种作用被完全抵消。在恶病质患者中,HSL mRNA和蛋白质的表达水平分别增加了50%和100%(P = 0.005 - 0.03),这与体外脂解刺激密切相关(r = 0.7 - 0.9)。恶病质患者中,胰岛素对成熟脂肪细胞的抗脂解作用以及对分化前脂肪细胞的刺激脂解作用均未改变。因癌症恶病质以外的其他因素体重减轻的患者,其脂肪细胞脂解没有变化。总之,癌症恶病质患者脂肪细胞脂解增加并非由于非表观遗传因素或体重减轻本身,很可能是由于脂肪细胞HSL的表达和功能增强。选择性抑制这种酶可能会防止癌症患者脂肪流失。